Screening and diagnosis of hemoglobinopathies in Germany: Current state and future perspectives

• Published in: Scientific reports Vol. 12; no. 1; p. 9762
• Main Authors: Aramayo-Singelmann, Carmen, Halimeh, Susan, Proske, Pia, Vignalingarajah, Abinuja, Cario, Holger, Christensen, Morten O., Yamamoto, Raina, Röth, Alexander, Reinhardt, Dirk, Reinhardt, Hans Christian, Alashkar, Ferras
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 13.06.2022; Nature Publishing Group; Nature Portfolio
• Subjects: 692/308; 692/4017; 692/699; Diagnosis; Females; Hemoglobinopathy; Humanities and Social Sciences; Immigration; Medical screening; Morbidity; multidisciplinary; Patients; Pediatrics; Science; Science (multidisciplinary); Thalassemia; Germany; Turkey
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-022-13751-8

This monocentric study conducted at the Pediatric and Adult Hemoglobinopathy Outpatient Units of the University Hospital of Essen summarizes the results of hemoglobinopathies diagnosed between August 2018 and September 2021, prior to the introduction of a general newborn screening (NBS) for SCD in Germany (October 2021). In total, 339 patients (pts.), 182 pediatric [50.5% males (92/182)] and 157 adult pts. [75.8% females (119/157)] were diagnosed by molecular analysis. The most common (parental) descent among affected pts. were the Middle Eastern and North African/Turkey (Turkey: 19.8%, Syria: 11.8%, and Iraq: 5.9%), and the sub-Saharan African region (21.3%). Median age at diagnosis in pediatric carriers [N = 157; 54.1% males (85/157)] was 6.2 yrs. (range 1 (months) mos.–17.8 yrs.) and 31 yrs. (range 18–65 yrs.) in adults [N = 53; 75.2% females (115/153)]. Median age at diagnosis of homozygous or compound-heterozygous disease in pediatric pts. (72% (18/25) females) was 3.7 yrs., range 4 mos.–17 yrs. (HbSS (N = 13): 2.5 yrs., range 5 mos.–7.8 yrs.; HbS/C disease (N = 5): 8 yrs., range 1–8 yrs.; homozygous/compound heterozygous β-thalassemia (N = 5): 8 yrs., range 3–13 yrs.), in contrast to HbH disease (N = 5): 18 yrs. (median), range 12–40 yrs. Hemoglobinopathies represent a relevant health problem in Germany due to immigration and late diagnosis of second/third generation migrants. SCD-NBS will accelerate diagnosis and might result in reduction of disease-associated morbidity. However, diagnosis of carriers and/or disease-states (i.e. thalassemic syndromes) in newly immigrated and undiagnosed patients will further be delayed. A first major step has been taken, but further steps are required.